



INTERIM FINANCIAL REPORT

Contents

Management Statement	3
Business Highlights	4
Financial Performance at a Glance	5
Financial Review First Half 2010	6
Group Operating Performance	6
Group Balance Sheet	7
Group Cash Position	7
Performance by Region	7
Important Developments	9
Major Developments - Organizational	9
Major Developments - Product Launches	10
Key Innovations - Product Pipeline	10
Outlook	10
Interim Financial Report	11
Consolidated Income Statement	11
Consolidated Statement of Comprehensive Income	12
Consolidated Balance Sheet	13
Condensed Consolidated Cash Flow Statement	14
Consolidated Statement of Changes in Equity	15
Selected notes to the condensed consolidated interim financial statements	16
General information	16
Summary of significant accounting policies	16
Segment reporting	17
Risk Management	18
Other Notes	18
Review report of the statutory auditor	20
Financial Calendar	21
Contact Information	21

Management Statement

The undersigned hereby declare that, to the best of their knowledge, the interim financial statements for the six-months period ended June 30, 2010, which have been prepared in accordance with the IAS 34 'Interim Financial Reporting' as adopted by the European Union, give a true and fair view of the equity, the financial situation and the results of Omega Pharma NV and the companies that are included in the consolidation scope.

The undersigned also declare that, to the best of their knowledge, the interim financial report provides a true and fair review of the important events that have occurred during the first six months of the financial year and of the other legally required information.

In the name and for the account of the Board of Directors

Marc Coucke, CEO

Barbara De Saedeleer, CFO

26 August 2010

Business Highlights



Sustained strong growth in Skin Care brands BodySol (+41%), ACO (+16%), and Cliniderm (+77%)




Paranix (+26%) head lice treatment and mosquito repellent Jungle Formula (+36%) remain on their growth path



Consumers' shift towards natural remedies and aromatherapy boosts Phytosun Arômes portfolio (+29%)



Innovative product roll outs on track with launch of new slimming range XLS Medical and Eczema treatment Dermalex Repair, on a country after country basis




Reinforced management structure and New composition of Board of Directors

More information on each topic can be found in this Interim Report under the section “Important Developments”.


Financial Performance at a Glance

- Total revenues increased by +3% to EUR 423.5 million
- Performance driven by strong growth in Emerging Markets and Belgium
- Revenue growth of the Five Pillars of +4%
- Execution of strategy drove EBITDA down by -11% to EUR 60.1 million
- EBITDA margin of 14.20%
- Net recurring result declined 14% to EUR 33.6 million
- FY10 target of 4% sales growth, >4% growth in EBITDA, and recurring EPS growth reiterated

Evolution Group Sales



Evolution Group EBITDA



1H10 at a glance

in EUR million

	1H10	1H09	YoY ¹
Group Sales	423.5	411.2	+3%
Gross Margin	225.9	223.7	+1%
Operating Costs ²	165.7	156.3	+6%
EBITDA ³	60.1	67.4	-11%
Net Recurring ⁴ Result	33.6	39.0	-14%
Net Recurring EPS	1.44	1.67	-14%
Average Number of Shares	23,347,309	23,347,309	0%

¹ YoY: year on year change in %

² Operating costs: services and other goods, personnel costs, and other

³ EBITDA: operating result before non-recurring items, increased with depreciations and amortization

⁴ Net result from continuing operations, including associates, after income tax and corrected for non-recurring items and their corresponding tax effects

Financial Review First Half 2010

Group Operating Performance

Group sales increased by 3% to EUR 423 million, which was mainly driven by a strong performance in Belgium and Emerging Markets. Overall, Omega Pharma's key skin care brands recorded double digit growth as did the Number One anti-head lice brand Paranix. In addition, consumers' trends towards natural remedies boosted sales of the aromatherapy portfolio Phytosun Arômes. In France, the pet care range Clément-Thékan performed particularly well.

The gross margin for the Group increased by EUR 2.17 million while the gross margin declined to 53.3% compared to 54.4% during the same period a year ago. Nevertheless, the gross margin evolution improved 1% compared to 1H09 (52.3%) and remained at the same level of FY09 (53.4%).

Higher investments in innovations and marketing activities in order to support the product roll outs planned for the second half of this year, impacted the Group's profitability. Also, additional restructuring charges to further optimize the business in France and some emerging countries weighed up on the Group's performance. As a result, Group EBIT stood at EUR 44.6 million compared to EUR 51.0 million during the first half of 2009.

The net financial result stood at -EUR 11.97 million compared to -EUR 13.32 million during first half 2009, mainly influenced by lower interest rate costs. In comparison with a net debt⁵ of EUR 380 million at 30 June 2009, the net debt at 30 June 2010 amounted to EUR 291 million.

The result from continuing operations before income tax amounted to EUR 32.67 million compared to EUR 39.93 million during the first half of 2009. However, following the accounting equity method, the result in 1H09 included the allocated result from the participation in Arseus of EUR 2.25 million. During the fourth quarter of 2009, the remaining stake in Arseus was sold.

The effective tax rate, as a percentage of result from continuing operations, was 13.6% for first half 2010.

The net recurring result for the Group amounted to EUR 33.6 million and the net recurring earnings per share came in at EUR 1.44 compared to EUR 1.67 last year, which also included however the allocated result from the participation in Arseus.

⁵ Net Financial debt: current and non-current liabilities, excluding current and non-current derivative financial instruments, minus cash and cash equivalents

Group Balance Sheet

Total assets increased by EUR 40.7 million to EUR 1,379 million mainly as a result of higher inventories, which rose by EUR 12 million due to product launches and portfolio expansion, and higher intangible assets related to research & development, patents, brands and consolidation goodwill.

Non current liabilities increased by EUR 27.8 million to EUR 397.2 million. The current liabilities decreased by EUR 2.2 million to EUR 306 million. Group equity increased by EUR 15.1 million and amounted to EUR 676.6 million.

Group Cash Position

The cash flow from operations amounted to EUR 32.30 million and was impacted by higher working capital requirements to support the various product launches. Hence, the cash outflow from the change in working capital amounted to EUR 15.8 million compared to a cash inflow from the change in working capital of EUR 31 million the same period a year ago.

Capital expenditure stood at EUR 17.39 million or 4.1% of Group sales and includes higher capitalized R&D, brand and patent costs. As a result, cash flow from investing activities amounted to EUR 21.30 million compared to EUR 12.11 million during the first half of 2009.

Finally, the 34% increase in dividend payments to EUR 16 million resulted in a lower net cash flow for the period ending 30 June 2010.

Performance by Region

in EUR million	Sales			EBITDA			
	1H10	1H09	YoY	1H10	Margin	1H09	YoY ⁶
Western Europe	175.8	174.9	+1%	35.4	20.1%	38.7	-9%
Belgium	124.6	112.0	+11%	18.2	14.6%	14.7	+24%
Emerging Markets	46.4	41.0	+13%	4.3	9.3%	10.5	-59%
France	76.7	83.3	-8%	9.1	11.9%	9.7	-6%
Corporate				-6.9		-6.2	
Group	423.5	411.2	+3%	60.1	14.2%	67.4	-11%

⁶ YoY: year on year evolution in %

Western Europe was impacted by the economic crisis in Greece, Portugal and Spain, and a poor performance in Germany. However, other countries such as the Nordics, Italy and UK, recorded solid sales growth. That said, higher investments in marketing activities such as TV advertisements to support new product launches, were not fully offset by the sales growth. EBITDA for the region amounted to EUR 35.45 million. The EBITDA margin stood at 20.14% compared to 22.20% the same period a year ago.

Belgium remained an important contributor to overall performance, thanks to the double digit sales growth in both OTC and generics. EBITDA increased by a solid +23.8% to EUR 18.22 million driven by the strong sales growth. As a result, the EBITDA margin improved to 14.61% versus 13.13% during first half 2009.

Emerging Markets were hit by destocking activities in Russia and Ukraine. Despite that, sales growth for the first half year was solid at +13% driven by Eastern Europe and Turkey. As the region is expected to be an important contributor for long term growth, the Company continued to invest in R&D, multiple product roll outs, new business structures and new people. Hence, EBITDA came in lower compared to the first half of 2009 and amounted to EUR 4.29 million

Sales in **France** continued to see the impact of the divestment of the Marseille factory end of 2009 and a delayed re-stocking by some wholesalers. However, the structural turnaround is progressing well, which is reflected in the pharmacists' orders that increased for the first time in years. In addition, thanks to an improved cost structure and a more optimized organization, the decrease in EBITDA was lower than the sales decline, which resulted in a slightly better EBITDA margin of 11.9% compared to 11.6% the same period a year ago.

Important Developments

During the first six months of the year, Omega Pharma has made enormous progression, both on organizational and R&D level, which set strong fundamentals for future growth.

Major Developments - Organizational

Omega Pharma has implemented a new matrix organization and has hired key industry experts to further strengthen the management structure at Corporate and Regional levels. This new centralized matrix structure has been set up as part of the Operational Excellence Phase, which has been initiated end of last year with the goal to further optimize operations at all levels of the organization.

In addition, the company has further strengthened its resources in innovation and marketing to ensure the successful execution of the five pillar strategy. This centralized marketing and innovation department complements the locally managed teams and supports all affiliates from the Group in the roll out of new products.

Furthermore, the structural turnaround in France is progressing well with the new Country Manager who took seat beginning of January. Key initiatives that have been taken to improve the business include a focused marketing, sales and supply organization, a better internal communication and a more cohesive structure. An example of a more controlled approach towards marketing is the renewed focus on TV advertisement, which has a more instant impact on consumers.

Finally, during the Annual General Meeting of May 3rd, a new composition of the Board of Directors has been approved with the appointment of two new independent directors Karel Van Eetvelt and Chris Van Doorslaer, the reappointment of Lucas Laureys NV as non-executive director and chairman, the reappointment of Jan Boone as independent director, and the appointment of Benoit Graulich BVBA as non-executive director. The Annual General Meeting approved all other resolutions for decisions included in the agenda, and hence also approved the annual accounts for the period ended December 31, 2009.

Major Developments - Product Launches

Key corporate (centralized) product initiatives that been launched at the end of 1H10 include the new range of slimming products XLS Medical and the cortisone-free eczema cream Dermalex Repair. Both products have been initially launched in selected European countries, with the gradual roll-out foreseen across the Group member countries during the remainder of the year, and beyond. In addition to key innovations fueled from the Central Marketing Department, local initiatives, such as cross-selling and local launches, further drove overall sales performance.

Key Innovations - Product Pipeline

As part of the innovation and R&D initiatives, a number of new projects are set for roll-out before year end. These include expansions under the Silence and Dermalex brands, and a new and improved Paranix anti-head lice product range. In addition, Omega Pharma will continue the gradual international roll-out of the products that were launched at end of 1H10. Furthermore, cross-selling activities and local initiatives in individual countries will complement centrally steered launches during the remainder of the year. Beyond 2010, Omega Pharma is working on a number of innovations of existing products as well as new products under existing brands. All these developments should enable the company to achieve its long term target of doubling sales of the 5 pillars Derma - Para - Cough & Cold - Classics - Multi Locals.

Outlook ⁽¹⁾

Thanks to the gradual roll out of new products, the ongoing optimization of the Group and lower financing costs, management reiterates the outlook for the full year 2010 and expects group sales growth of 4% EBITDA growth of above 4% and significant EPS growth.

⁽¹⁾ Disclaimer: This press release contains forward-looking information based on current internal estimates and expectations as well as market expectations. Forward-looking statements involve inherent risks and apply exclusively on the date they are stated. Actual results may materially differ from those included in the forward-looking statements. Given the reduced visibility inherent to the current economic environment, such differences between expectations and reality can vary more significantly than before.

Interim Financial Report

Consolidated Income Statement

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	January - June 2010	January - June 2009
Operating Income	427 017	415 144
Turnover	423 474	411 156
Other operating income	3 543	3 988
Operating expenses	(382 372)	(364 141)
Trade goods	(197 597)	(187 447)
<i>Trade goods purchased</i>	<i>(210 128)</i>	<i>(186 111)</i>
<i>Changes in inventories of raw materials, components, work in progress and finished goods</i>	<i>12 531</i>	<i>(1 336)</i>
Services and other goods	(117 240)	(106 852)
Employee benefit expenses	(48 628)	(50 363)
Depreciations and amortization	(8 726)	(8 773)
Changes in write-offs stocks & trade receivables	(454)	(1 696)
Changes in provisions for liabilities	(437)	181
Other operating expenses	(9 290)	(9 192)
<i>Of which other</i>	<i>(2 977)</i>	<i>(3 286)</i>
<i>Of which restructuring charges</i>	<i>(6 313)</i>	<i>(5 905)</i>
Operating result	44 645	51 003
Financial income	614	476
Financial expense	(12 586)	(13 799)
Financial result	(11 972)	(13 322)
Result from companies included in accounting equity method		2 247
Result from continuing operations before income tax	32 673	39 927
Income tax	(4 456)	(5 922)
Net Result	28 217	34 005
Share of non controlling interests	126	(157)
Net result of the Group	28 343	33 848
Total number of shares outstanding at June 30	24 227 303	24 227 303
Of which treasury shares	879 994	879 994
Weighted average after deduction of treasury shares at June 30	23 347 309	23 347 309
Earnings per share (in EUR)	1.21	1.45
Earnings per share excluding companies in acc equity method (in EUR)	1.21	1.36
Earnings per share excluding non-recurring items ⁽¹⁾ (in EUR)	1.44	1.67
Diluted earnings per share ⁽²⁾ (in EUR)	1.20	1.45

⁽¹⁾ Based on Net result for the Group minus restructuring costs and tax effect of restructuring costs

⁽²⁾ Taking into account the dilutive impact of outstanding warrants which are "in the money" (i.e. 23 347 309 weighted average number of shares + 284 452 warrants)

Consolidated Statement of Comprehensive Income

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	Fair value & other reserves	Cumulative translation adjustments	Retained earnings	Non- controlling Interests	Total equity
Fair value gains/(losses) on cash flow hedges	(8 509)				(8 509)
Fair value gains/(losses) on cash flow hedges - tax effect	2 892				2 892
Currency translation adjustments		1 885			1 885
Profit for the period			33 849	157	34 006
Total comprehensive income for the period ended 30 June 2009	(5 617)	1 885	33 849	157	30 274

<i>(in EUR thousand)</i>	Fair value & other reserves	Cumulative translation adjustments	Retained earnings	Non- controlling Interests	Total equity
Fair value gains/(losses) on cash flow hedges	1 742				1 742
Fair value gains/(losses) on cash flow hedges - tax effect	(592)				(592)
Currency translation adjustments		4 391			4 391
Profit for the period			28 343	(126)	28 217
Total comprehensive income for the period ended 30 June 30	1 150	4 391	28 343	(126)	33 758

Consolidated Balance Sheet

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	30 June 2010	31 December 2009
Non-current assets	1 003 440	987 882
Intangible assets	916 914	905 319
Property, plant and equipment	41 952	43 244
Financial assets	1 939	1 940
Deferred income tax assets	33 976	29 028
Other non-current assets	8 659	8 351
Current assets	375 695	350 570
Inventories	121 796	109 794
Trade receivables	169 136	164 223
Other current assets	51 269	51 324
<i>Of which deferred income taxes</i>	<i>20 237</i>	<i>22 534</i>
Cash and cash equivalents	33 494	25 229
TOTAL ASSETS	1 379 135	1 338 452
EQUITY	675 634	660 518
Share capital and share premium	366 841	366 841
Retained earnings	334 884	325 219
Treasury shares	(24 144)	(24 144)
Fair value and other reserves	(126)	(1 284)
Cumulative translation adjustments	(2 268)	(6 659)
Non-controlling interests	447	545
LIABILITIES	703 501	677 934
Non-current liabilities	397 235	369 473
Provisions	3 389	4 475
Pension obligations	4 820	4 587
Deferred income tax liabilities	72 718	71 947
Borrowings	315 152	258 332
<i>Of which fair value of hedged part of the USPP</i>	<i>1 164</i>	<i>(26 698)</i>
Other non-current liabilities	495	61
Derivative financial instruments	661	30 071
Current liabilities	306 266	308 461
Borrowings (current financial liabilities)	10 767	19 085
Trade payables	220 304	215 731
Taxes, remuneration and social security	53 858	48 836
Taxes, VAT and other tax costs	41 219	35 076
Remuneration and social security costs	12 639	13 760
Other current payables	21 337	24 809
Derivative financial instruments		
TOTAL EQUITY AND LIABILITIES	1 379 135	1 338 452

Condensed Consolidated Cash Flow Statement

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	January - June 2010	January-June 2009
Profit before income tax and associates	32 673	37 680
Taxes paid	(2 378)	2 796
Adjustments for operational non-cash items	8 305	13 668
Adjustments for interests and financial non-cash items	9 501	11 843
Gross cash flow from operating activities	48 101	65 986
Changes in working capital	(15 802)	31 098
Cash flow from operating activities	32 299	97 084
Capital expenditure	(17 385)	(9 338)
Capital disposals	121	347
Cash and cash equivalents from acquisitions	0	75
Investments in existing and new participations (post payments)	(4 034)	(5 442)
Dividends received	0	2 250
Cash flow from investing activities	(21 298)	(12 109)
Proceeds from the issue of share capital	0	0
Purchases of own shares	0	0
Dividend distribution	(15 969)	(11 859)
Change in debt	20 490	(52 296)
Interests received (paid)	(8 007)	(12 266)
Cash flow from financing activities	(3 486)	(76 421)
Net increase/decrease of cash flows for the period	7 515	8 554
Cash and cash equivalents - beginning of the period	25 229	33 793
Gains or losses on currency exchange on liquid assets	750	129
Cash and cash equivalents - end of the period	33 494	42 476
Total net cash flow of the period	7 515	8 554

Consolidated Statement of Changes in Equity

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	Number of shares	Share capital and share premium	Treasury shares	Fair value & other reserves	Cumulative translation adjustments	Retained earnings	Non- controlling Interests	Total equity
Balance at 31 December 2008	23 347 309	366 841	(24 144)	4 641	(9 850)	262 815	217	600 520
Total comprehensive income for the period ended 30 June 2009				(5 617)	1 885	33 849	157	30 274
Capital increases		0						0
Employee share options scheme				17				17
Dividend on treasury shares						528		528
Dividend						(14 536)		(14 536)
Share of movement in reserves of investments accounted for according to the equity method						102		102
Non-controlling interests							66	66
Balance at 30 June 2009	23 427 309	366 841	(24 144)	(959)	(7 965)	282 758	440	616 971
Balance at 31 December 2009	23 347 309	366 841	(24 144)	(1 284)	(6 659)	325 219	545	660 518
Total comprehensive income for the period ended 30 June 2010		0	0	1 150	4 391	28 343	(126)	33 758
Capital increases		0						0
Employee share options scheme				8				8
Dividend on treasury shares						704		704
Dividend						(19 382)		(19 382)
Non-controlling interests							28	28
Balance at 30 June 2010	23 347 309	366 841	(24 144)	(126)	(2 268)	334 884	447	675 634

Selected notes to the condensed consolidated interim financial statements

General information

Omega Pharma is a pure play in OTC with focus on prescription-free medicines and personal care products. The company's brands are clustered around five pillars, including Derma (both cosmetics and medicated skin care), Cough & Cold (including allergy), Parasites, Classics (Omega Pharma Heritage) and Multi-Locals. Since its creation in 1987, the company has expanded from its Belgian home base into 35 countries across Europe and beyond, and is now positioned within the Top Fifteen ranking of the global OTC market.

The company's shares are listed on the regulated market Euronext Brussels.

The condensed consolidated interim financial statements for the six months' period ended 30 June 2010 have been prepared in accordance with IAS 34 "Interim Financial Reporting" as adopted by the European Union. This document should be read together with the consolidated annual accounts for the period 2009 (including the significant accounting policies) as published in the 2009 annual report, which is available on www.omega-pharma.be (Investor Center).

These condensed consolidated interim financial statements have been approved for publication by the Board of Directors of August 25th 2010. They have been submitted to a limited review by the Statutory Auditor.

Summary of significant accounting policies

The principal accounting policies applied in preparation of these consolidated interim financial report are identical to those applied in preparation of the consolidated financial statements for the year ended on December 31, 2009.

A summary of the principal accounting policies can be found on the pages 74 to and including 83 of the 2009 annual report, which can be consulted and downloaded via the following web link: <http://www.omega-pharma.be/EN/pdf/E-2009%20vr%20web.pdf>.

The following new standards and amendments to standards are mandatory for the financial year beginning January 1st 2010 and have been adopted by the Group when relevant:

- IFRS 3 (revised) "Business Combinations" (effective 1 July 2009)
- IAS 27 (revised) "Consolidated and separate financial statements" (effective 1 July 2009)
- Annual improvements 2009 (effective 1 January 2010)

- Amendment to IAS 39 “Financial instruments. Recognition and measurement”, on Eligible hedged items (effective 1 July 2009)
- Amendment to IFRS2 “Share based payments- Group cash-settled share-based payment transactions” (effective 1 January 2010)
- IFRIC 12 “Service concession arrangements”. (effective 1 January 2008, EU endorsed 30 March 2009)
- IFRIC 15 “Arrangements for construction of real estate” (effective 1 January 2009 but EU endorsed for 1 January 2010)
- IFRIC 16 “Hedges of a net investment in a foreign operation (effective 1 October 2008 but EU endorsed for 1 July 2009)
- IFRIC 17 “Distributions of non cash assets to owners” (effective 1 July 2009)
- IFRIC 18 “Transfer of assets from customers” (EU endorsed for annual periods beginning on or after 31 October 2009)

The following new standards, amendments to standards and interpretations, endorsed by the EU, have been issued but are not effective for the financial year beginning January 1st 2010 and have not been early adopted:

- Revised IAS 24 “Related Party Disclosures” (effective 1 January 2011)
- Amendments to IAS 32 “Classification of Rights Issues” (effective 1 February 2010)
- Amendment to IFRIC 14 “Prepayment of a Minimum Funding Requirement” (effective 1 January 2011)

Segment reporting

During the first half of 2010, the segment reporting has not changed compared to the first six months ending 30 June 2009.

The segment results for the period ending June 30, 2009 are as follows:

<i>Figures submitted to a limited review, IFRS in thousand euro</i>	Total turnover	Inter-segment turnover	Net turnover	EBITDA ⁷	Operating result of the segment
Belgium	117 019	-5 054	111 965	14 716	12 460
France	85 276	-1 936	83 340	9 655	9 425
Western Europe	187 284	-12 412	174 872	38 796	32 342
Emerging Markets	40 979	0	40 979	10 450	7 502

⁷ Operating result before non-recurring items, increased with depreciations and amortization

Not allocated	-	-	-	-6 238	-10 726
Total Omega Pharma	430 558	-19 402	411 156	67 377	51 003

Reconciliation with the result from ordinary activities before income tax

Depreciations and amortization	-	-	-10 469		
Non-recurring items (restructuring charges)			- 5 905		
Financial result			- 13 322		
Net result from associated companies			2 247		
Result from ordinary activities before income tax			39 927		

The segment results for the period ending June 30, 2010 are as follows:

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	Total turnover	Inter-segment turnover	Net turnover	EBITDA⁸	Operating result of the segment
Western Europe	189 428	-13 716	175 712	35 449	30 287
Belgium	133 122	-8 482	124 640	18 219	16 437
Emerging Markets	47 346	-934	46 412	4 294	1 201
France	78 198	-1 488	76 710	9 142	5 422
Not allocated	-	-	-	-6 966	-8 702
Total Omega Pharma	448 094	-24 620	423 474	60 138	44 645

Reconciliation with the result from ordinary activities before income tax

Depreciations and amortization	-	-	-9 179		
Non-recurring items (restructuring charges)			-6 314		
Financial result			-11 972		
Result from ordinary activities before income tax			32 673		

Risk Management

At closing of the interim period ended on June 30, 2010, Omega Pharma cannot distinguish any other risks than those included in the pages 84 to and including 91 of the 2009 annual report: <http://www.omega-pharma.be/EN/pdf/E-2009%20vr%20web.pdf>.

Other Notes

1. Income tax

The amount of the income taxes is a management estimate and is based on an expected average tax rate of 13.6% for the entire accounting period 2010.

⁸ Operating result before non-recurring items, increased with depreciations and amortization

2. Associates

For the period ending 30 June 2010, no participations are recognized on the balance sheet according to the equity method. The remaining 24% stake in Arseus was sold during the fourth quarter 2009.

3. Equity - treasury shares

In accordance with article 620 of the Belgian Company Code, the Extraordinary General Meetings of Shareholders of 9 June 2009 granted authorization of the Board of Directors to buy back Company shares.

During the first six months of 2010, no use has been made of this authorization. On 30 June 2010, Omega Pharma held 879,994 treasury shares which were previously purchased, and which then represented a total amount of EUR 24.1 million.

4. Contingencies

During the first six months of 2010, no material changes occurred to the situation as described in Note 21 on page 127 of the 2009 annual report.

5. Business combinations

During the first six months of 2010, no acquisitions have been done.

6. Related parties

Related parties refer to the members of the Executive Committee and the non-executive members of the Board of Directors. The 24% stake in Arseus NV was sold in the fourth quarter of 2009.

The remuneration of the members of the Executive Committee and the non-executive members of the Board of Directors is determined on an annual basis, for which reason no further details are included in this interim financial report.

The chart hereunder provides an overview of the transactions between the Company and Arseus NV in the period from January 1 to and including June 30, 2010.

<i>in EUR thousand</i>	January-June 2010	January-June 2009
Sale of goods and services	0	116
Sale of goods to Arseus companies	0	108
Sale of services to Arseus companies	0	8
Purchase of goods and services	0	92
Purchase of goods from Arseus companies	0	92
Purchase of services from Arseus companies	0	0

7. Significant events after the balance sheet date

No significant events occurred after 30 June 2010

Review report of the statutory auditor

We have reviewed the accompanying consolidated condensed consolidated interim financial statements of Omega Pharma NV (“the Company”) and its subsidiaries (jointly “the Group”), as of and for the six-month period ended 30 June 2010, consisting of the interim consolidated balance sheet, the related consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity and condensed consolidated cash flow statement for the six month period then ended, as well as the selected explanatory notes, with a balance sheet total of EUR’000 1.379.135 and a profit for the period, part of the Group, of EUR’000 28.343. The board of directors is responsible for the preparation and fair presentation of these consolidated condensed interim financial statements in accordance with IAS 34 as adopted by the European Union. Our responsibility is to express a conclusion on these consolidated interim financial statements based on our review.

We conducted our review in accordance with International Standard on Review Engagements 2410, “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the consolidated condensed interim financial statements referred to above are not prepared, in all material respects, in accordance with IAS 34 as adopted by the European Union.

Antwerp, 26 August 2010

PricewaterhouseCoopers Bedrijfsrevisoren
Represented by

Peter Van den Eynde
Statutory auditor

Financial Calendar

19 October 2010 (5:45 pm) - 3Q10 Trading Update

20 January 2011 (5:45 pm) - 4Q10 and FY10 Trading Update

28 February 2011 (5:45 pm) - FY10 Results

Contact Information

Marieke Vermeersch - Investor Relations Officer

marieke.vermeersch@omega-pharma.be

Tel +32 9 381 03 31